Mazdutide Shows Promise in Controlling blood sugar and Obesity in Diabetes Patients: Study

Analysis of seven RCTs involving a total of 680 participants revealed the superiority of Mazdutide over placebo in various aspects. The drug showed effectiveness in reducing body weight, systolic and diastolic blood pressure, total cholesterol, triglycerides, low-density lipoprotein and high-density lipoprotein.

Mazdutide demonstrated positive effects in the management of hemoglobin A1c (HbA1c) and fasting plasma glucose levels in individuals with type 2 diabetes which underlines its potential as a multifaceted therapeutic approach.

Further analysis through subgroup and meta-regression analyses unveiled nuances, where weight reduction was notable and more significant in non-diabetic individuals when compared to the diabetics, especially among the individuals who were undergoing longer treatment durations (24 weeks).

The outcomes of this study also highlighted a pertinent concern regarding the safety profile of Mazdutide. While the drug expressed promising efficacy, the participants reported transient mild to moderate gastrointestinal side effects which suggests a need for careful monitoring and management strategies.

Reference:

Nalisa, D. L., Cuboia, N., Dyab, E., Jackson, I. L., Felix, H. J., Shoki, P., Mubiana, M., Oyedeji-Amusa, M., Azevedo, L., & Jiang, H. (2024). Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials. In Frontiers in Endocrinology (Vol. 15). Frontiers Media SA. https://doi.org/10.3389/fendo.2024.1309118